1.Symptomatic subependymoma: a case report.
Yong Koo PARK ; Woo Suk CHOI ; Won LEEM ; Youn Wha KIM ; Moon Ho YANG
Journal of Korean Medical Science 1990;5(2):111-115
Subependymoma is a rare, slow-growing, benign noninvasive tumor of the central nervous system that may be located in the fourth ventricle, the septum pellucidum, the third and the lateral ventricles, the aqueduct, and the proximal spinal cord. Symptoms, if any, usually result either from direct compression of the brain stem or from acute hydrocephalus due to occlusion of the foramen of Monro or aqueduct of Sylvius. In this report, we describe a case of subependymoma of the lateral ventricle with headache in a young female patient. This is the first reported case subependymoma in Korea that was documented along with Magnetic resonance image.
Adult
;
Cerebral Ventricle Neoplasms/*diagnosis/pathology
;
Female
;
Glioma/*drug therapy/pathology
;
Headache/complications
;
Humans
;
Magnetic Resonance Imaging
2.Glioblastoma in a Patient with Neurofibromatosis Type 1: A Case Report and Review of the Literature.
Brain Tumor Research and Treatment 2014;2(1):36-38
Neurofibromatosis type 1 (NF1) is an autosomal dominantly inherited familial tumor syndrome. Benign tumors such as pilocytic astrocytoma, optic glioma make up the majority of intracranial neoplasms in patients with NF1. There have only been a handful of cases in which adult glioblastoma presented with NF1. A 32-year-old male presented with headache and radiological studies showing a high grade intra-axial tumor. The patient underwent gross total surgical excision and the pathology revealed glioblastoma. After the surgery, he received concomitant chemo-radiotherapy with temozolomide and adjuvant temozolomide chemotherapy. We report a NF1 patient who developed glioblastoma and reviewed related articles.
Adult
;
Astrocytoma
;
Brain Neoplasms
;
Drug Therapy
;
Glioblastoma*
;
Hand
;
Headache
;
Humans
;
Male
;
Neurofibromatosis 1*
;
Optic Nerve Glioma
;
Pathology
3.Efficacy of Gamma Knife Radiosurgery for Recurrent High-Grade Gliomas with Limited Tumor Volume
Young Jun CHEON ; Tae Young JUNG ; Shin JUNG ; In Young KIM ; Kyung Sub MOON ; Sa Hoe LIM
Journal of Korean Neurosurgical Society 2018;61(4):516-524
OBJECTIVE: This study aims to determine whether gamma knife radiosurgery (GKR) improves survival in patients with recurrent highgrade gliomas.METHODS: Twenty nine patients with recurrent high-grade glioma underwent 38 GKR. The male-to-female ratio was 10 : 19, and the median age was 53.8 years (range, 20–75). GKR was performed in 11 cases of recurrent anaplastic oligodendrogliomas, five anaplastic astrocytomas, and 22 glioblastomas. The median prescription dose was 16 Gy (range, 10–24), and the median target volume was 7.0 mL (range, 1.1–15.7). Of the 29 patients, 13 (44.8%) received concurrent chemotherapy. We retrospectively analyzed the progression-free survival (PFS) and overall survival (OS) after GKR depending on the Eastern Cooperative Oncology Group (ECOG) performance status (PS), pathology, concurrent chemotherapy, radiation dose, and target tumor volume.RESULTS: Starting from when the patients underwent GKR, the median PFS and OS were 5.0 months (range, 1.1–28.1) and 13.0 months (range, 1.1–75.1), respectively. On univariate analysis, the median PFS was significantly long in patients with anaplastic oligodendroglioma, ECOG PS 1, and target tumor volume less than 10 mL (p < 0.05). Meanwhile, on multivariate analysis, patients with ECOG PS 1 and target tumor volume less than 10 mL showed improved PFS (p=0.043 and p=0.007, respectively). The median OS was significantly increased in patients with ECOG PS 1 and tumor volume less than 10 mL on univariate and multivariate analyses (p < 0.05).CONCLUSION: GKR could be an additional treatment option in recurrent high-grade glioma, particularly in patients with good PS and limited tumor volume.
Astrocytoma
;
Disease-Free Survival
;
Drug Therapy
;
Glioblastoma
;
Glioma
;
Humans
;
Multivariate Analysis
;
Oligodendroglioma
;
Pathology
;
Prescriptions
;
Radiosurgery
;
Recurrence
;
Retrospective Studies
;
Tumor Burden
4.Glioma-related edema: new insight into molecular mechanisms and their clinical implications.
Chinese Journal of Cancer 2013;32(1):49-52
Glioma-related edema (GRE) is a significant contributor to morbidity and mortality from glioma. GRE is a complicated process involving not only peritumoral edema but also the water content of the tumor body. In terms of etiology, this condition derives from both GRE in the untreated state and GRE secondary to clinical intervention, and different cell types contribute to distinct components of GRE. Peritumoral edema was previously believed to loosen glioma tissue, facilitating tumor-cell invasion; however, the nutrition hypothesis of the tumor microecosystem suggests that tumor cells invade for the sake of nutrition. Edema is the pathologic consequence of the reconstructed trophic linkage within the tumor microecosystem. Glioma cells induce peritumoral brain edema via an active process that supplies a suitable niche for peritumoral invasive cells, suggesting that glioma-related peritumoral brain edema is determined by the invasive property of tumor cells. There are differences between pivotal molecular events and reactive molecular events in the development of GRE. Molecular therapy should target the former, as targeting reactive molecular events will produce undesired or even adverse results. At present, brain glioma angiogenesis models have not been translated into a new understanding of the features of brain images. The effect of these models on peritumoral brain edema is unclear. Clinical approaches should be transformed on the basis of new knowledge of the molecular mechanism underlying GRE. Exploring clinical assessment methods, optimizing the existing control strategy of GRE, and simultaneously developing new treatments are essential.
Brain Edema
;
diagnosis
;
drug therapy
;
metabolism
;
pathology
;
Brain Neoplasms
;
diagnosis
;
drug therapy
;
metabolism
;
pathology
;
Glioma
;
diagnosis
;
drug therapy
;
metabolism
;
pathology
;
Humans
;
Magnetic Resonance Imaging
;
Molecular Targeted Therapy
;
Vascular Endothelial Growth Factor A
;
metabolism
5.Adenovirus mediated IL-24 gene expression inhibits growth of human glioma cell in vitro.
Yunbo SHAN ; Weihua SHENG ; Yufeng XIE ; Tielian LIU ; Yingying JING ; Zhiqing HU ; Jicheng YANG
Chinese Journal of Biotechnology 2009;25(2):279-286
To investigate the inhibitory effect and anti-cancer mechanism of adenovirus mediated IL-24 gene expression on the human U251 glioma cell. U251 glioma cells were infected with Ad-IL-24 at various multiplicity of infection (MOIs). Cell proliferation was determined by MTT assay. Cell apoptosis was detected by flow cytometry and Hochest staining. The transcription of apoptosis-related genes was analyzed by reverse transcription-PCR (RT-PCR), and the expression of Cleaved Caspase-3 was analyzed by Western blotting. The result showed that the growth of U251 glioma cells was significantly inhibited by Ad-IL-24 at the MOI of 100. The apoptotic rate of U251 glioma cells was 42% 72 h after infection with Ad-IL-24. Four days after infection, the growth of the U251 glioma cells was inhibited to 50%. RT-PCR showed that Ad-IL-24 not only up-regulated expression of bax/bcl-2, ICE, C-myc, p53 and down-regulated the expression of HIF-1alpha, but also enhanced Caspase-3 activation, eventually resulting apoptosis. Taken together, these results suggest that infection of U251 glioma cells with Ad-IL-24 can inhibit growth and induce apoptosis significantly by the regulation of apoptosis-related genes.
Adenoviridae
;
genetics
;
metabolism
;
Apoptosis
;
Brain Neoplasms
;
genetics
;
pathology
;
Cell Proliferation
;
drug effects
;
Genetic Therapy
;
Glioma
;
genetics
;
pathology
;
Humans
;
Interleukins
;
genetics
;
metabolism
;
Recombination, Genetic
;
Tumor Cells, Cultured
6.Photodynamic therapy mediated by 5-aminolevulinic acid suppresses gliomas growth by decreasing the microvessels.
Wei YI ; Hai-tao XU ; Dao-feng TIAN ; Li-quan WU ; Shen-qi ZHANG ; Long WANG ; Bao-wei JI ; Xiao-nan ZHU ; Humphrey OKECHI ; Gang LIU ; Qian-xue CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2015;35(2):259-264
Although 5-aminolevulinic acid (5-ALA)-mediated photodynamic therapy (PDT) has been demonstrated to be a novel and effective therapeutic modality for some human malignancies, its effect and mechanism on glioma are still controversial. Previous studies have reported that 5-ALA-PDT induced necrosis of C6 rat glioma cells in vitro. The aim of this study was to further investigate the effect and mechanism of 5-ALA-PDT on C6 gliomas implanted in rats in vivo. Twenty-four rats bearing similar size of subcutaneously implanted C6 rat glioma were randomly divided into 3 groups: receiving 5-ALA-PDT (group A), laser irradiation (group B), and mock procedures but without any treatment (group C), respectively. The growth, histology, microvessel density (MVD), and apoptosis of the grafts in each group were determined after the treatments. As compared with groups B and C, the volume of tumor grafts was significantly reduced (P<0.05), MVD was significantly decreased (P<0.001), and the cellular necrosis was obviously increased in group A. There was no significant difference in apoptosis among the three groups. The in vivo studies confirmed that 5-ALA-PDT may be an effective treatment for gliomas by inhibiting the tumor growth. The mechanism underlying may involve increasing the cellular necrosis but not inducing the cellular apoptosis, which may result from the destruction of the tumor microvessels.
Aminolevulinic Acid
;
pharmacology
;
therapeutic use
;
Animals
;
Brain Neoplasms
;
blood supply
;
drug therapy
;
pathology
;
Cell Line, Tumor
;
Glioma
;
blood supply
;
drug therapy
;
pathology
;
Microvessels
;
drug effects
;
Photochemotherapy
;
Photosensitizing Agents
;
pharmacology
;
therapeutic use
;
Rats
;
Rats, Wistar
;
Xenograft Model Antitumor Assays
7.Brainstem Glioma: Survival and Prognostic Factors.
Hee Won JUNG ; Heon YOO ; Kyu Chang WANG ; Dong Gyu KIM ; Hyun Jib KIM ; Dae Hee HAN ; Kil Soo CHOI ; Byung Kyu CHO
Journal of Korean Neurosurgical Society 1999;28(11):1556-1568
OBJECTIVE: To clarify the biological behavior and prognostic factors of brain stem gliomas, the authors reviewed 48 patients with brain stem gliomas treated between 1980 and 1996. PATIENTS AND METHOD: The clinical presentation, tumor location, pathology, and treatment modalities were correlated with the prognosis of these tumors. Male to female ratio was 1.1:1, with the median age of 12.5 years. Thirty patients(63%) were below 15 years old, and 18 patients(38%) were of adult ages. Mean follow up period was 21.8 months. RESULTS: Focal tumors were in 22 cases and diffuse tumors were in 26. All nine midbrain tumors were focal type. Twenty-two(92%) cases among 24 potine tumors were diffuse type and two cases were focal type as dorsally exophytic tumor. Eleven(73%) cases among 15 medullary and cervicomedullary tumors were focal type and four(27%) cases were diffuse type. Pathologically, there were 14 anaplastic astrocytomas, 11 low grade astrocytomas, 4 glioblastomas, 3 oligodendrogliomas, and 1 ganglioglioma. Fifteen tumors were diagnosed only radiologically without histologic verification. Surgery was done in 33 patients(gross total or subtotal removal in 8, biopsy or partial removal in 15, stereotactic biopsy in 10). Radiation therapy was given in 41 patients(conventional in 29, hyperfractionated in 12). Chemotherapy was done in four patients. CONCLUSION: Statistically significant prognostic factors were symptom duration prior to diagnosis(p=0.0004), cranial nerve palsy(p=0.0206), extent of tumor growth(p=0.0219), contrast enhancement(p=0.0226), intratumoral cyst(p=0.047), histopathological grading(p=0.0304), surgery in patients with focal tumors(p=0.0018), and radiation therapy(p=0.0149).
Adolescent
;
Adult
;
Astrocytoma
;
Biopsy
;
Brain Stem Neoplasms
;
Brain Stem*
;
Cranial Nerves
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Ganglioglioma
;
Glioblastoma
;
Glioma*
;
Humans
;
Male
;
Oligodendroglioma
;
Pathology
;
Prognosis
;
Survival Rate
8.Improvements in quality of care resulting from a formal multidisciplinary tumour clinic in the management of high-grade glioma.
Michael F BACK ; Emily L L ANG ; Wai-Hoe NG ; Siew-Ju SEE ; C C Tchoyoson LIM ; Lee-Lee TAY ; Tseng-Tsai YEO
Annals of the Academy of Medicine, Singapore 2007;36(5):347-351
INTRODUCTIONThere is increasing belief that a formal protocol-based multidisciplinary care model should be adopted as an optimal care model in oncology. However, there is minimal outcome evidence to demonstrate an improvement in patient care. The aim of this study was to compare clinical quality outcomes between patients with high-grade glioma managed at one hospital using a formal neuro-oncology multidisciplinary tumour clinic (MTC) and a second hospital with a traditional on-call referral pattern (non-MTC).
MATERIALS AND METHODSPatients with high-grade glioma managed radically with radiation therapy at 2 Singapore hospitals from May 2002 to May 2006 were entered into a prospective database. Patients were grouped into management via MTC or non-MTC. Four clinical quality indicators were chosen retrospectively to assess the variation in practice: a) Use of computed tomography (CT) or magnetic resonance (MR) imaging post-resection (POI) for assessment of residual disease; b) Commencement of radiation therapy (RT) within 28 days of surgery; c) Adjuvant chemotherapy use for glioblastoma multiforme (CTGBM) and d) Median survival.
RESULTSSixty-seven patients were managed radically, with 47 by MTC and by 20 by non-MTC. MTC patients were more likely to have POI (P = 0.042), and CTGBM (P = 0.025). Although the RT start time was similar for the whole cohort (60% versus 45%: P = 0.296); for GBM patients, the RT start was earlier (63% vs 33% P = 0.024). The median survival for the MTC group was 18.7 months versus 11.9 months for the non-MTC group (P = 0.11).
CONCLUSIONClinical quality outcomes were significantly improved in patients with high-grade glioma managed in this neuro-oncology MTC.
Cancer Care Facilities ; Female ; Glioma ; classification ; drug therapy ; pathology ; radiotherapy ; Humans ; Interdisciplinary Communication ; Male ; Middle Aged ; Prospective Studies ; Quality Indicators, Health Care ; Quality of Health Care ; Survival Analysis
9.Bilateral Thalamic Glioma in a Young Woman: a Case Report
Brain & Neurorehabilitation 2019;12(2):e17-
Bilateral thalamic gliomas (BTGs) are rare brain tumors. In general, the prognosis is poor because of the involvement of bilateral thalami and limitations of surgical excision. Consequently, patients with symptoms of personality changes and memory impairment must be differentiated from others. Magnetic resonance imaging (MRI) is essential for the diagnosis of BTGs and reveals a hypo-intense lesion on T1-weighted images and a hyper-intense lesion on T2 images. We report a case of a 17-year-old female patient suffering from progressive cognitive dysfunction and personality changes and subsequent rehabilitation treatment. Brain MRI showed an enlarged bilateral thalamus, with hyperintensity on T2-weighted images and iso-intensity on T1-weighted images. A biopsy was performed, and the pathology revealed a high-grade glioma. The patient was referred for radiotherapy and chemotherapy. She also underwent rehabilitation treatment for 5 weeks and showed improvement in standing balance, endurance, and speech fluency. The patient's Modified Barthel Index scores also improved. Cancer rehabilitation is important in brain tumor patients because they have a higher incidence of neurological sequelae than others. Rehabilitation of patients with a malignant brain tumor is also important for improving health-related quality of life by maintaining the general condition and preventing complications during and after cancer treatment.
Adolescent
;
Biopsy
;
Brain
;
Brain Neoplasms
;
Diagnosis
;
Drug Therapy
;
Female
;
Glioma
;
Humans
;
Incidence
;
Magnetic Resonance Imaging
;
Memory
;
Memory Disorders
;
Neurobehavioral Manifestations
;
Pathology
;
Prognosis
;
Quality of Life
;
Radiotherapy
;
Rehabilitation
;
Thalamus
10.Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.
Chae Young KIM ; Soon Hye PARK ; Moonsup JEONG ; O Seo KWON ; Hyounmie DOH ; Su Hyung KANG ; Paul D ROBBINS ; Byong Moon KIM ; Dai Wu SEOL ; Byung Gee KIM
Experimental & Molecular Medicine 2011;43(10):580-586
Malignant glioma is the most frequent type in brain tumors. The prognosis of this tumor has not been significantly improved for the past decades and the average survival of patients is less than one year. Thus, an effective novel therapy is urgently needed. TNF-related apoptosis inducing ligand (TRAIL), known to have tumor cell-specific killing activity, has been investigated as a novel therapeutic for cancers. We have developed Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy and demonstrated the potential to treat malignant gliomas. Currently, this Ad-stTRAIL gene therapy is under phase I clinical trial for malignant gliomas. Here, we report preclinical studies for Ad-stTRAIL carried out using rats. We delivered Ad-stTRAIL intracranially and determined its pharmacokinetics and biodistribution. Most Ad-stTRAIL remained in the delivered site and the relatively low number of viral genomes was detected in the opposite site of brain and cerebrospinal fluid. Similarly, only small portion of the viral particles injected was found in the blood plasma and major organs and tissues, probably due to the brain-blood barrier. Multiple administrations did not lead to accumulation of Ad-stTRAIL at the injection site and organs. Repeated delivery of Ad-stTRAIL did not show any serious side effects. Our data indicate that intracranially delivered Ad-stTRAIL is a safe approach, demonstrating the potential as a novel therapy for treating gliomas.
Adenoviridae/genetics
;
Animals
;
Blood-Brain Barrier
;
Brain/drug effects/*metabolism/pathology
;
Brain Neoplasms/genetics/metabolism/pathology/*therapy
;
Clinical Trials, Phase I as Topic
;
DNA, Viral/metabolism
;
Disease Models, Animal
;
Drug Delivery Systems
;
Drug Evaluation, Preclinical
;
*Gene Therapy
;
Glioma/genetics/metabolism/pathology/*therapy
;
Humans
;
Liver/drug effects/metabolism/pathology
;
Protein Multimerization/genetics
;
Rats
;
Spleen/drug effects/metabolism/pathology
;
TNF-Related Apoptosis-Inducing Ligand/genetics/*pharmacokinetics